Iron metabolism and diagnostic of iron deficiency in inflammatory bowel diseases.

T. Boyko

doi:10.26641/2307-0404.2013.3.18995

Авторы

T. Boyko SI “Institute of Gastroenterology of NAMS of Ukraine”, Ukraine

DOI:

https://doi.org/10.26641/2307-0404.2013.3.18995

Ключевые слова:

anemia, chronic inflammatory bowel diseases, iron deficiency

Аннотация

According to WHO data about 2 billion people in the world suffer from anemia, that is 1/3 of the whole population of the planet. Causes of anemic states are varied and often they complement each other, iron deficiency anemia (IDA) which occurs in 75-80% of cases is of the greatest significance among anemias of different origins. Anaemia is a frequent systemic manifestation of inflammatory bowel diseases (IBD) which significantly worsens quality of life, it is associated with disease severity and resistance to therapy. The article highlights pathogenesis and diagnosis of anaemia in IBD patients based on current understanding of iron homeostasis in chronic inflammation. 69 anemic patients with IBD compared to with 30 patients with normal Hb level were under investigation. The control group consisted of 15 healthy individuals. The examination included total blood count, parameters of iron metabolism (serum iron, unsaturated and total iron binding capacity, trasferrin saturation, ferritin), as well as hepcidin-25 level and erythropoetin in serum. Depending on sTfR/log ferritin index the patients were divided into groups: 44% with IDA, 34 % – anemia of chronic disease (ACD) and 22 % – combination of IDA and ACD. A significant decrease of hepcidine-25 level in serum of IDA patients and increase of that one against inflammatory process in patients with ACD and ACD+IDA was found being. An increase of erythropoetin production was established in anemic patients, less expressed on ACD background.

Библиографические ссылки

Виговська Я.І. Анемія хронічних хвороб: пато¬генез, діагностика, лікування (лекція) / Я.І. Виговська // Укр. мед. часопис. – 2012. – № 6 (92). – С. 76–79.

Видиборець С.В. Гепсидин – як центральний ре¬гулятор метаболізму заліза / С.В. Видиборець, А.В. Сер¬гієнко, Ю.Ю. Попович // Укр. журнал гемато¬логії та трансфузіології. – 2011. – № 2. – С. 5–9.

Гепсидин как регулятор гомеостаза железа / А.А. Левина, Т.В. Казюкова, Н.В. Цветаева [и др.] // Педи¬атрия. – 2008. – Т. 87, № 1. – С. 67-74.

Діагностика та лікування захворювань сис¬теми крові Посібник для студентів та лікарів-інтернів / А.С. Свінціцький, С.А. Гусєва, С.В. Скрипниченко [та ін.]. – К.: Медкнига, 2010. – 148 с.

Залізодефіцитні стани: посібник для лікарів / за ред. С.А. Гусєвої [та ін.]. – К.: Логос, 2005. – 76 с.

Колочева Т.И. Ферритин в лабораторной ди¬а¬гностике различных заболеваний человека / Т.И. Колочева, С.С. Решетников // Новости "Вектор-Бест".  2007.  № 1 (43).  Режим доступа к журн.: http://www.vector-best.ru/nvb/n43/st43_4.htm.

Рекомбінантний еритропоетин: застосування в клі¬нічній практиці / С.А. Гусєва, Я.П. Гончаров, К.В. Ку¬рищук [та ін.]. – К.: Логос, 2007 – 131 с.

Ganz T: Hepcidin, a key regulator of iron me¬tabolism and mediator of anemia of inflammation / T. Ganz // Blood. – 2003. – Vol. 102. – P. 783-788.

Gomollon F. Anemia and inflammatory bowel di¬seases / F. Gomollon, J. Gisbert // World J. Gastroenterol. – 2009. – Vol. 15, N 37. – P. 4659–4665.

Intestinal DMT1 cotransporter is down regulated by hepcidin via proteasome internalization and deg¬radation / C. Brasse-Lagnel, Z. Rarim, P. Letteron [et al.] // Gastroenterol. – 2011. – Vol. 140, N 4. – P. 1261-1271.

Iron, anaemia, and inflammatory bowel diseases / C. Gasche, M.C. Lomer, I. Cavill [et al.] // Gut. – 2004. – Vol. 53, N 8. – P. 1190–1197.

Milman N. Anemia – still a major health problem in many parts of the world! / N. Milman // Ann. Hematol. – 2011. – Vol. 90. – P. 369–377.

Nemeth E. The role of hepcidin in iron meta¬bolism / E. Nemeth, T. Ganz // Acta Hematol. – 2009. – Vol. 122, N 2-3. – P. 78-86.

Serum soluble transferrin receptor reflects ery¬thro¬poiesis but not iron availability in erythropoietin-treated chronic hemodialysis patients / W.C. Chiang, T.J. Tsai, Y.M. Chen [et al.] // Clin. Nephrol. 2002. – Vol. 58. – P. 363–369.

Skikne B.S. Serum transferring receptor / B.S. Ski¬kne // Am. J. Hematol. – 2008. – Vol. 83, N 11. – P. 872-875.

Stin J. Diagnosis and management of iron defi¬ciency anemia in patients with IBD / J. Stin, F. Hartmann, A.U. Dignas // Nature Revue Gastroent. Hepatol. – 2010. – Vol. 7, N 11. – P. 599-610.

The ratio of serum transferring receptor and serum ferritin in the diagnosis of iron status / B.I. Malope, A.P. MacPhail, M. Alberts [et al.] // Br. J. Haematol. – 2001 – Vol.115. – P. 84-89.

Wish J.B. Assessing Iron Status: Beyond Serum Ferritin and Tanserrin Saturation / J.B. Wish // Clin. J. Amer. Cociety Nephrology. – 2006. – Vol. 1, Suppl. 1. – S4-S8.

World Health Organization. Assessing the iron status of populations. Geneva, WHO 2007. - Режим дос¬тупа к журн.: http://www.who.int/entity/nutrition/

World Health Organization.Worldwide preva¬lence of anaemia 1993– 2005. WHO Global Database on Anaemia. – Geneva: WHO, 2008.

Vygovska YaІ. Anemia of chronic diseases: pa¬tho¬genesis, diagnosis, treatment (lecture). Ukr Med Chasopys. 2012;6(92):76-79.

Vidiborets SV, Sergienko AV, Popovich YuYu. Hepcidine as a central regulator of iron metabolism. Ukr J Hematol Transfusiol. 2011;2:5-9.

Levina AA, Kazyukova TV, Tsvetaeva NV. Hep¬cidine as a regulator of iron homeostasis. Pediatry. 2008;87(1):67-74.

Svintsitskiy AS, Guseva SA, Skripnichenko SV. Diagnostic and treatment of blood system diseases. Kyi'v: Medkniga. 2010:148.

Guseva SA. Iron deficiency condition. Kyi'v: Logos. 2005:76.

Kolocheva TI, Reshetnikov SS. Ferritin in labo¬ratory diagnostic of different human diseases. Vector-Best News; 2007:1(43).

Guseva SA, Goncharov YaP, Kurshchuk КV. Recombinant erythropoietin: use in clinic practice. Kyi'v: Logos. 2007:131.

Ganz T. Hepcidin, a key regulator of iron meta¬bolism and mediator of anemia of inflammation. Blood. 2003;102:783-8.

Gomollon F, Gisbert J. Anemia and inflammatory bowel diseases. World J. Gastroenterol. 2009;15 (37):4659-65.

Brasse-Lagnel C, Rarim Z, Letteron P. Intestinal DMT1 cotransporter is down regulated by hepcidin via proteasome internalization and degradation. Gastroen¬te¬rol. 2011;140(4):1261-71.

Gasche C, Lomer MC, Cavill I. Iron, anaemia, and inflammatory bowel diseases. Gut. 2004;53(8):1190-7.

Milman N. Anemia – still a major health problem in many parts of the world! Ann. Hematol. 2011;90:369-77.

Nemeth E, Ganz T. The role of hepcidin in iron metabolism. Acta Hematol. 2009;122(2-3):78-86.

Chiang WC, Tsai TJ, Chen YM. Serum soluble transferrin receptor reflects erythropoiesis but not iron availability in erythropoietin-treated chronic hemodialysis patients. Clin. Nephrol. 2002;58:363–9.

Skikne BS. Serum transferring receptor. Am. J. He¬matol. 2008;83(11):872-5.

Stin J, Hartmann F, Dignas AU. Diagnosis and management of iron deficiency anemia in patients with IBD. Nature Revue Gastroent. Hepatol. 2010;7(11):599-610.

Malope BI, MacPhail AP, Alberts M. The ratio of serum transferring receptor and serum ferritin in the diagnosis of iron status. Br. J. Haematol. 2001;115:84-89.

Wish JB. Assessing Iron Status: Beyond Serum Ferritin and Tanserrin Saturation. Clin. J. of the American Cociety of Nephrology. 2006;1(Suppl.1):4-8.

World Health Organization. Assessing the iron status of populations. Geneva, WHO 2007.

World Health Organization.Worldwide preva¬lence of anaemia 1993– 2005. WHO Global Database on Anaemia. Geneva, WHO 2008.